Niacin formulation
The present invention provides a composition including an amphiphilic compound capable of self-assembling into a liquid crystalline phase; and a niacin compound. In another aspect, the present invention provides a method for the treatment of a disease state comprising administering a therapeutically effective amount of a pharmaceutical composition incorporating that composition.
1. A composition formulated for administration by mucosal delivery,
wherein the composition comprises an amphiphilic compound capable of self-assembling into a liquid crystalline phase and a therapeutically effective amount of a niacin compound,
wherein the amphiphilic compound forms a self-assembled structure that includes the niacin compound when the composition is contacted with a hydrophilic solvent; and
wherein, following formation of the self-assembled structure, the niacin compound is released from the self-assembled structure into the hydrophilic solvent.
2. A composition according to claim 1 , wherein the self-assembled structure is cubic phase or hexagonal phase.
3. A composition according to claim 2 , further including at least one anti-flushing supplement, and wherein the anti-flushing supplement is a sugar cane derived extract comprising polyphenols and/or flavonoids.
4. A composition according to claim 1 , further including at least one stabiliser.
5. A composition according to claim 1 , in which the amphiphilic compound is a mono- and/or di-glyceride of a fatty acid comprising a 6 to 24 carbon chain.
6. A composition according to claim 5 , wherein the fatty acid is oleic acid.
7. A composition according to claim 6 , wherein the amphiphilic compound is a glycerol monooleate.
8. A composition according to claim 1 , in which the niacin compound is niacin.
9. A composition according to claim 1 , further including a statin.
10. A self-assembled structure including the composition according to claim 1 and a hydrophilic solvent.
11. A muccoadhesive tablet including the composition according to claim 1 , wherein the unit dosage of the niacin compound comprises 100 mg to 1,000 mg.
12. A muccoadhesive tablet according to claim 11 , wherein upon administration; the amphiphilic compound forms a self-assembled structure that includes the niacin compound; the tablet disintegrates into particles including the self-assembled structures; and the particles adhere to the buccal muccosa.
13. A muccoadhesive tablet according to claim 11 , further including an enhancer for enhancing the buccal delivery of the niacin.
14. A muccoadhesive tablet according to claim 11 , wherein the self-assembled structure prolongs the release of the niacin.
15. A method for reducing a subject's total cholesterol comprising buccal administration of a therapeutically effective amount of a composition according to claim 1 .
16. A method according to claim 15 , wherein the method treats hyperlipidaemia, dyslipidaemia, cardiovascular disease, atherosclerosis, or a combination thereof.
17. A method according to claim 15 , wherein the buccal administration is sublingual administration.
18. A method of preparing the self-assembled structure according to claim 10 including the steps of mixing an amphiphilic compound and a niacin compound and dispersing the mixture in a hydrophilic solvent to produce a self-assembled structure.
19. A composition according to claim 1 , wherein the release of the niacin compound occurs over at least 4 to 6 hours.
20. A composition according to claim 1 , wherein the weight of niacin compound when dry is at least 50% by weight of the combined weight of the dry niacin compound and the dry amphiphilic compound.
21. A composition formulated for administration by mucosal delivery,
wherein the composition comprises an amphiphilic compound capable of self-assembling into a liquid crystalline phase and a therapeutically effective amount of a niacin compound,
wherein the amphiphilic compound forms a self-assembled structure that includes the niacin compound when the composition is contacted with a hydrophilic solvent; and
wherein the weight of the amphiphilic compound when dry is at least 5% by weight of the combined weight of the dry niacin compound and the dry amphiphilic compound.
22. A composition according to claim 21 , wherein the self-assembled structure prolongs the release of the niacin compound for up to 12 hours.
23. A composition according to claim 21 , wherein the composition does not comprise prolonged release polymers.